GAIN
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – A phase III study utilizing the German Registry of Incidental Gallbladder Carcinoma Platform (GR) – The AIO/ CALGP/ ACO- GAIN-Trial
III
interventionell
National
Cisplatin, Gemcitabin
Status: In Rekrutierung
Zeitraum
2019
2023
Zentren
50
37
Zentren gesucht
Patienten
300
32
30.03.2022
Klinische Settings
peri-operativ
front line
kurativ
Beteiligte
AIO-Arbeitsgruppen
Sponsor
Institute of Clinical Cancer Research (IKF) Krankenhaus Nordwest
Kooperierende Fachgesellschaft(en)
ACO
DGAV-CALGP
Förderer
DFG
Identifier
AIO-HEP-0118/ass
GAIN/GEM/CIS
2017-004444-38
Kontakt
Leitung
PD Dr. med. Thorsten Oliver Götze
Ansprechpartner*in
PD Dr. med. Thorsten Oliver Götze
Telefon +49 69 7601-4420
E-Mail Goetze.Thorsten@khnw.de